From: Real-life cost-effectiveness of benralizumab in patients with severe asthma
Variables | Baseline | 3 months | 6 months | 12 months | p* |
---|---|---|---|---|---|
ACT, mean (SD) | 13.7 (4.1) | 20.1 (3.6) | 20.8 (2.9) | 21.3 (2.2) | < 0.001 |
Controlled asthma (ACT ≥ 20), n (%) | 2 (4.5) | 25 (56.8) | 36 (81.8) | 39 (92.9) | < 0.001 |
Number of ED visits in the previous year, mean (SD) | 4.1 (2.6) | – | – | 0.7 (1.6) | < 0.001 |
Number of severe exacerbations in the previous year, mean (SD) | 5.50 ± 2.63 | – | – | 0.66 ± 0.94 | < 0.001 |
Corticosteroid-dependent, n (%) | 18 (40.9) | 16 (36.4) | 9 (20.5) | 8 (18.2) | < 0.001 |
Inhaled budesonide (or equivalent) dose, μg/day, mean (SD) | 993 (485) | 853 (446) | 773 (408) | 693 (343) | < 0.001 |
Oral prednisone dose, mg/day, mean (SD) | 19.3 (8.8) | 10 (8.6) | 5.3 (7.8) | 3.9 (7.2) | < 0.001 |
Number of courses of OCS (previous year), mean (SD) | 5.8 (3.3) | – | – | 1 (1.6) | < 0.001 |
FEV1 mL, mean (SD) | 1459 (509) | 1697 (495) | 1732 (621) | 1833 (556) | < 0.001 |
FEV1%, mean (SD) | 66.1 (14) | 74.3 (12.2) | 77 (14.5) | 78.3 (15) | < 0.001 |
Blood eosinophil count, cells/μL, mean (SD) | 730.9 (288) | 18 (18) | 14.9 (13.7) | 2.7 (4) | < 0.001 |